DexCom surprised investors on July 30 with solid quarterly figures and a slight increase in its annual forecast, causing shares to rise 0.44 percent to $89.74 in after-hours trading. Revenue climbed 15.2 percent to $1.157 billion in the second quarter of 2025, a respectable performance though noticeably slower than 2024’s 21 percent growth. International expansion also cooled, with growth of just 11 percent compared to 15 percent the previous year. Profitability indicators showed concerning trends as the gross margin fell from 63.5 to 60.1 percent, while operating margin slightly decreased from 19.5 to 19.2 percent. Nevertheless, the company increased its profits to $179.8 million ($0.45 per share), surpassing last year’s $143.5 million ($0.35 per share).
Outlook and Challenges
A closer examination of business segments reveals structural challenges, with sensor business growing by 17 percent while hardware sales plummeted by 37 percent. Management hopes the recent FDA approval for their 15-day sensor will provide new momentum, offering users the advantage of changing sensors every 15 days instead of 10. The company has modestly raised its annual forecast from $4.6 billion to between $4.6 and $4.625 billion, while maintaining optimistic margin projections of approximately 62 percent gross margin and 21 percent operating margin. The coming quarters will reveal whether DexCom can maintain its growth story despite increasing competition.
